ストックスクリーナーアプリを入手
9.03
2.27%
0.20
アフターアワーズ：
9.00
-0.03
-0.33%
前日終値:
$8.83
開ける：
$8.93
24時間の取引高:
1.53M
Relative Volume:
1.08
時価総額：
$896.68M
収益：
$84.28M
当期純損益:
$-171.30M
株価収益率:
-5.1977
EPS:
-1.7373
ネットキャッシュフロー:
$-171.21M
1週間 パフォーマンス:
+13.73%
1か月 パフォーマンス:
+8.80%
6か月 パフォーマンス:
-0.22%
1年 パフォーマンス:
-36.68%
1日の値動き範囲:
$8.845
$9.13
1週間の範囲:
$7.65
$9.13
52週間の値動き範囲:
$6.66
$18.90
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
名前
Ars Pharmaceuticals Inc
セクター
電話
858-771-9307
住所
11682 EL CAMINO REAL, SUITE 300, SAN DIEGO
Compare SPRY vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
9.03 | 876.82M | 84.28M | -171.30M | -171.21M | -1.7373 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-09 | 開始されました | Northland Capital | Outperform |
| 2025-11-04 | 再開されました | Roth Capital | Buy |
| 2025-09-04 | 開始されました | Roth Capital | Buy |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2025-02-10 | 開始されました | Oppenheimer | Outperform |
| 2024-08-20 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-08-13 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2024-08-12 | 繰り返されました | Leerink Partners | Outperform |
| 2024-07-25 | 開始されました | Raymond James | Outperform |
| 2024-03-05 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-02-20 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2023-09-20 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | 開始されました | Wedbush | Outperform |
| 2023-01-03 | 開始されました | William Blair | Outperform |
| 2022-12-13 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Ars Pharmaceuticals Inc (SPRY) 最新ニュース
How The ARS Pharmaceuticals (SPRY) Narrative Is Shifting With Fresh Analyst Models And Approvals - Yahoo Finance
SPRY Stock Price, Quote & Chart | ARS PHARMACEUTICALS INC (NASDAQ:SPRY) - ChartMill
[ARS] SUPERNUS PHARMACEUTICALS, INC. SEC Filing - Stock Titan
[ARS] Eledon Pharmaceuticals, Inc. SEC Filing - Stock Titan
[ARS] Zentalis Pharmaceuticals, Inc. SEC Filing - Stock Titan
[ARS] RECURSION PHARMACEUTICALS, INC. SEC Filing - Stock Titan
[ARS] Milestone Pharmaceuticals Inc. SEC Filing - Stock Titan
[ARS] Olema Pharmaceuticals, Inc. SEC Filing - Stock Titan
[ARS] RHYTHM PHARMACEUTICALS, INC. SEC Filing - Stock Titan
[ARS] ARS Pharmaceuticals, Inc. SEC Filing - Stock Titan
ARS Pharmaceuticals (NASDAQ: SPRY) sets 2026 meeting, highlights neffy launch and cash runway - Stock Titan
[ARS] MADRIGAL PHARMACEUTICALS, INC. SEC Filing - Stock Titan
[ARS] IRONWOOD PHARMACEUTICALS INC SEC Filing - Stock Titan
[ARS] Oric Pharmaceuticals, Inc. SEC Filing - Stock Titan
ARS Pharmaceuticals, Inc. (SPRY) soars 7.1%: Is further upside left in the stock? - MSN
[ARS] Armata Pharmaceuticals, Inc. SEC Filing - Stock Titan
BlackRock (SPRY) files amendment showing 4.98% ownership - Stock Titan
Epinephrine Nasal Spray Approved for Severe Allergic Reactions in EU - respiratory-therapy.com
Avoiding Lag: Real-Time Signals in (SPRY) Movement - Stock Traders Daily
[ARS] REGENERON PHARMACEUTICALS, INC. SEC Filing - Stock Titan
[ARS] AGIOS PHARMACEUTICALS, INC. SEC Filing - Stock Titan
ARS Pharmaceuticals Q3 2025 Earnings Preview - MSN
[ARS] Vanda Pharmaceuticals Inc. SEC Filing - Stock Titan
[ARS] Acumen Pharmaceuticals, Inc. SEC Filing - Stock Titan
[ARS] LB PHARMACEUTICALS INC SEC Filing - Stock Titan
[ARS] IONIS PHARMACEUTICALS INC SEC Filing - Stock Titan
[ARS] BIOCRYST PHARMACEUTICALS INC SEC Filing - Stock Titan
ARS Pharmaceuticals, Inc. (SPRY) Soars 7.1%: Is Further Upside Left in the Stock? - Yahoo Finance
[ARS] Amylyx Pharmaceuticals, Inc. SEC Filing - Stock Titan
[ARS] Xenon Pharmaceuticals Inc. SEC Filing - Stock Titan
FDA Approves Neffy Needle-Free Epinephrine Nasal Spray for Younger Children - respiratory-therapy.com
[ARS] PMV Pharmaceuticals, Inc. SEC Filing - Stock Titan
[ARS] LIGAND PHARMACEUTICALS INC SEC Filing - Stock Titan
[ARS] Shuttle Pharmaceuticals Holdings, Inc. SEC Filing - Stock Titan
[ARS] Verrica Pharmaceuticals Inc. SEC Filing - Stock Titan
FDA Approves Expanded Use for ARS Pharmaceuticals Nasal Spray - HarianBasis.co
Northland Highlights ARS Pharmaceuticals, Inc. (SPRY) Needle-Free Therapy as Major Innovation Driver - Insider Monkey
Pharma-Bio Serv (PBSV) posts $9.0M revenue, margins lift in Europe - Stock Titan
ARS Pharmaceuticals (SPRY) Stock: Breakdown Signals (Nudges Up) 2026-04-16Social Momentum Signals - UBND thành phố Hải Phòng
neffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) - Sahm
neffy® Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions - Investing News Network
Health Canada approves neffy nasal spray for severe allergies By Investing.com - Investing.com Australia
William Blair Maintains ARS Pharmaceuticals(SPRY.US) With Buy Rating - Moomoo
Health Canada approves neffy nasal spray for severe allergies - Investing.com
Health Canada Approves neffy Nasal Spray for Anaphylaxis Treatment in Canada, Available Summer 2026 - Quiver Quantitative
neffy® (epinephrine nasal spray) Approved in Canada as the - GlobeNewswire
Discipline and Rules-Based Execution in SPRY Response - Stock Traders Daily
[ARS] Amphastar Pharmaceuticals, Inc. SEC Filing - Stock Titan
Q1 Earnings Forecast for SPRY Issued By Northland Securities - MarketBeat
Rally Mode: Can ARS Pharmaceuticals Inc sustain earnings growth2026 Reactions & Community Trade Idea Sharing Platform - baoquankhu1.vn
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Ars Pharmaceuticals Inc (SPRY) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):